Overview
- BullFrog AI announced Monday a commercial deal with an unnamed top‑five drugmaker to use its bfLEAP platform to find and rank drug targets for major depressive disorder.
- bfLEAP applies causal modeling to large, mixed biological datasets to surface targets that could advance more quickly into drug programs.
- The agreement grants the pharmaceutical partner exclusive access to one target candidate identified through the work.
- BullFrog said a forthcoming SEC Form 8‑K will provide additional terms that have not been disclosed.
- Shares jumped, with BFRG more than doubling Monday and BFRGW up over 35%, after CEO Vin Singh called the pact strong third‑party validation that could broaden the relationship.